Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific A1CF ACF, ACF64, ACF65, APOBEC1CF, ASP ENSG00000148584 APOBEC1 complementation factor 10 50799409-50885675 Predicted intracellular proteins Evidence at protein level HPA037779, HPA044079 Supported Supported Nucleoplasm Tissue enriched Tissue enhanced duodenum: 24.2;liver: 75.9;small intestine: 30.4 kidney: 13.3 AATK AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77 ENSG00000181409 Apoptosis-associated tyrosine kinase 17 81117295-81166077 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009073 Supported Uncertain Mitochondria Mixed Tissue enhanced cerebral cortex: 36.5;duodenum: 24.0 small intestine: 18.7 AC009133.22 ENSG00000277669 16 29663279-29695144 Predicted secreted proteins Evidence at protein level HPA011887 Uncertain Not detected Tissue enhanced colon: 2.7;duodenum: 1.9;spleen: 1.0 lung: 0.4 ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Supported Approved Vesicles Expressed in all Tissue enhanced duodenum: 183.8;small intestine: 297.5 testis: 83.7 ACY3 ACY-3, HCBP1, MGC9740 ENSG00000132744 Aminoacylase 3 11 67642555-67650659 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039219, HPA048187 Supported Endometrial cancer:4.80e-4 (favourable) Mixed Tissue enhanced duodenum: 82.8;kidney: 53.1;small intestine: 80.3 cervix, uterine: 16.0 ADAT3 TAD3 ENSG00000213638 Adenosine deaminase, tRNA-specific 3 19 1905378-1913447 Predicted intracellular proteins Evidence at protein level HPA058899 Uncertain Approved Nucleus Head and neck cancer:6.13e-4 (favourable), Stomach cancer:6.98e-4 (favourable) Expressed in all Tissue enhanced duodenum: 7.7 small intestine: 5.4 ADGRG4 GPR112, PGR17, RP1-299I16 ENSG00000156920 Adhesion G protein-coupled receptor G4 X 136300963-136416888 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035324 Uncertain Not detected Tissue enhanced duodenum: 2.6;small intestine: 1.7 fallopian tube: 0.5 ADH1C ADH3 ENSG00000248144 Alcohol dehydrogenase 1C (class I), gamma polypeptide 4 99336492-99353027 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 522.4;liver: 886.9;stomach: 478.6 colon: 281.0 AKR1B10 AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI ENSG00000198074 Aldo-keto reductase family 1, member B10 (aldose reductase) 7 134527592-134541408 Predicted intracellular proteins Evidence at protein level HPA020280, CAB070163, HPA073633 Supported Supported Plasma membrane
Cytosol Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 653.4;gallbladder: 284.3;small intestine: 396.0;stomach: 417.4 esophagus: 90.2 AKR1C3 ENSG00000282883 Aldo-keto reductase family 1, member C3 10 5048812-5107503 Predicted intracellular proteins Evidence at protein level HPA068265 Approved Nucleus
Nucleoli fibrillar center
Endoplasmic reticulum
Cytosol Tissue enhanced duodenum: 254.5;gallbladder: 246.9 small intestine: 168.3 AKR7A3 ENSG00000162482 Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 1 19282558-19289250 Predicted intracellular proteins Evidence at protein level HPA064638 Approved Cytosol Renal cancer:8.80e-7 (favourable) Group enriched Tissue enhanced duodenum: 175.1;small intestine: 109.2 stomach: 69.3 ANKS4B FLJ38819, HARP ENSG00000175311 Ankyrin repeat and sterile alpha motif domain containing 4B 16 21233665-21253845 Predicted intracellular proteins Evidence at protein level HPA043523 Approved Approved Nucleoplasm
Cytosol Group enriched Tissue enhanced duodenum: 18.6;rectum: 15.9;small intestine: 26.3 colon: 13.9 ANO9 PIG5, TMEM16J, TP53I5 ENSG00000185101 Anoctamin 9 11 417933-442011 Predicted membrane proteins, Transporters Evidence at protein level HPA039948, HPA040112 Approved Uncertain Golgi apparatus Urothelial cancer:8.81e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 32.4;small intestine: 31.6 skin: 21.6 AQP11 ENSG00000178301 Aquaporin 11 11 77589391-77610355 Predicted membrane proteins, Transporters Evidence at protein level HPA042879 Approved Approved Nucleoplasm
Vesicles Ovarian cancer:9.89e-4 (favourable) Mixed Tissue enhanced duodenum: 24.8;small intestine: 23.6 adrenal gland: 10.1 ARHGDIG RHOGDI-3 ENSG00000242173 Rho GDP dissociation inhibitor (GDI) gamma 16 268727-283010 Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced cerebral cortex: 131.5;duodenum: 45.5 small intestine: 18.2 ARHGEF16 GEF16, NBR ENSG00000130762 Rho guanine nucleotide exchange factor (GEF) 16 1 3454426-3481113 Predicted intracellular proteins Evidence at protein level HPA010609 Approved Renal cancer:1.24e-10 (favourable), Liver cancer:1.82e-4 (unfavourable) Mixed Tissue enhanced duodenum: 43.3 small intestine: 36.6 B3GNT8 B3GALT7, beta3Gn-T8, BGALT15 ENSG00000177191 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 19 41425359-41428730 Predicted secreted proteins Evidence at protein level HPA043669 Supported Pancreatic cancer:9.31e-6 (favourable), Endometrial cancer:4.11e-4 (unfavourable) Mixed Tissue enhanced duodenum: 16.0;small intestine: 17.2 esophagus: 10.7 BAIAP2L2 FLJ22582 ENSG00000128298 BAI1-associated protein 2-like 2 22 38084889-38110670 Predicted intracellular proteins Evidence at protein level HPA003043 Approved Expressed in all Tissue enhanced duodenum: 110.2;small intestine: 99.5 gallbladder: 27.6 BCL2L15 Bfk, C1orf178, FLJ22588 ENSG00000188761 BCL2-like 15 1 113878168-113887547 Predicted intracellular proteins Evidence at protein level HPA029732, HPA029733 Approved Endometrial cancer:5.63e-4 (favourable) Tissue enhanced Tissue enhanced colon: 48.1;duodenum: 68.4;rectum: 52.8;small intestine: 65.6 stomach: 24.2 BCO1 BCDO, BCDO1, BCMO, BCMO1, FLJ10730 ENSG00000135697 Beta-carotene oxygenase 1 16 81238448-81291142 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA043811 Uncertain Actin filaments
Microtubule organizing center Mixed Tissue enhanced duodenum: 8.9;small intestine: 15.1 kidney: 3.3 C6orf222 DKFZp779B1540 ENSG00000189325 Chromosome 6 open reading frame 222 6 36315757-36336885 Predicted intracellular proteins Evidence at protein level HPA038407, HPA058189 Uncertain Group enriched Tissue enhanced duodenum: 25.4;small intestine: 26.9 rectum: 6.4 C8orf86 FLJ43582 ENSG00000196166 Chromosome 8 open reading frame 86 8 38510834-38528662 Predicted intracellular proteins Evidence at transcript level HPA025066 Uncertain Not detected Tissue enhanced duodenum: 1.0 small intestine: 0.5 CALML4 MGC4809, NY-BR-20 ENSG00000129007 Calmodulin-like 4 15 68190705-68206110 Predicted intracellular proteins Evidence at protein level HPA051109 Supported Approved Nucleoplasm
Golgi apparatus
Cytosol Mixed Tissue enhanced duodenum: 82.7;small intestine: 76.5 colon: 58.6 CBLC CBL-3, CBL-SL, RNF57 ENSG00000142273 Cbl proto-oncogene C, E3 ubiquitin protein ligase 19 44777869-44800634 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008087, HPA035266 Approved Approved Nucleoplasm Renal cancer:3.11e-6 (favourable) Mixed Tissue enhanced duodenum: 53.9;skin: 42.0;small intestine: 44.9 colon: 21.8 CCL15 HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3 ENSG00000275718 Chemokine (C-C motif) ligand 15 17 35996440-36002038 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058608 Approved Golgi apparatus
Vesicles Urothelial cancer:3.02e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 22.1;rectum: 31.0;small intestine: 27.2 colon: 19.3 CES3 ES31, FLJ21736 ENSG00000172828 Carboxylesterase 3 16 66961237-66975148 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041008, HPA041307 Approved Approved Nuclear membrane
Endoplasmic reticulum Liver cancer:7.26e-5 (favourable) Mixed Tissue enhanced colon: 37.9;duodenum: 31.3;rectum: 34.8 small intestine: 27.1 CHN2 ARHGAP3, RhoGAP3 ENSG00000106069 Chimerin 2 7 29122274-29514328 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018989 Approved Mixed Tissue enhanced duodenum: 76.8;small intestine: 69.8 cerebral cortex: 31.8 CHST6 MCDC1 ENSG00000183196 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 16 75472052-75495384 Disease related genes, Predicted secreted proteins Evidence at protein level Mixed Tissue enhanced cervix, uterine: 16.4;duodenum: 10.9;small intestine: 11.2 cerebral cortex: 7.9 CLRN1 RP61, USH3, USH3A ENSG00000163646 Clarin 1 3 150926163-150972999 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054636 Uncertain Not detected Tissue enhanced adrenal gland: 6.8;duodenum: 1.6 testis: 0.8 CTD-3214H19.16 ENSG00000269711 19 7678501-7682854 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced bone marrow: 14.1;duodenum: 7.9;lung: 11.8 appendix: 6.7 CYP2C19 CPCJ, CYP2C, P450IIC19 ENSG00000165841 Cytochrome P450, family 2, subfamily C, polypeptide 19 10 94762624-94853260 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015066 Supported Not detected Tissue enhanced duodenum: 49.7;liver: 125.5 small intestine: 21.2 CYP2S1 ENSG00000167600 Cytochrome P450, family 2, subfamily S, polypeptide 1 19 41193049-41207539 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049227 Approved Endoplasmic reticulum Renal cancer:1.60e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 99.4;small intestine: 70.0;stomach: 113.4 colon: 26.4 CYP2W1 FLJ20359, MGC34287 ENSG00000073067 Cytochrome P450, family 2, subfamily W, polypeptide 1 7 983199-989640 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012753 Uncertain Urothelial cancer:5.85e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 5.6;duodenum: 6.3;skin: 9.7 placenta: 1.4 CYP3A5 CP35, P450PCN3, PCN3 ENSG00000106258 Cytochrome P450, family 3, subfamily A, polypeptide 5 7 99648194-99679998 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Liver cancer:3.72e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 117.9;liver: 93.1;small intestine: 191.3 stomach: 79.3 CYP4F12 ENSG00000186204 Cytochrome P450, family 4, subfamily F, polypeptide 12 19 15672757-15697174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable) Group enriched Tissue enhanced duodenum: 37.1;small intestine: 43.1 skin: 22.4 DAB1 ENSG00000173406 Dab, reelin signal transducer, homolog 1 (Drosophila) 1 56994778-58546734 Predicted intracellular proteins Evidence at protein level CAB032329, HPA052033, HPA067495 Supported Validated Vesicles Mixed Tissue enhanced duodenum: 16.4;seminal vesicle: 13.7;small intestine: 25.3 prostate: 7.0 DDC AADC ENSG00000132437 Dopa decarboxylase (aromatic L-amino acid decarboxylase) 7 50458436-50565457 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA017742 Supported Approved Actin filaments Mixed Tissue enhanced duodenum: 159.5;kidney: 318.7;small intestine: 184.3 adrenal gland: 64.1 DGAT1 ARGP1, DGAT ENSG00000185000 Diacylglycerol O-acyltransferase 1 8 144314584-144326910 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032853 Supported Approved Nucleoli
Endoplasmic reticulum Expressed in all Tissue enhanced duodenum: 73.2;small intestine: 76.7 adipose tissue: 20.0 DHDH HUM2DD ENSG00000104808 Dihydrodiol dehydrogenase (dimeric) 19 48933682-48944969 Enzymes, Predicted intracellular proteins Evidence at protein level HPA044131 Approved Approved Nucleoplasm
Actin filaments Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable) Expressed in all Tissue enhanced duodenum: 10.5;kidney: 17.8;small intestine: 19.0 prostate: 4.6 DKK4 ENSG00000104371 Dickkopf WNT signaling pathway inhibitor 4 8 42374068-42377232 Predicted secreted proteins Evidence at protein level HPA052916 Approved Tissue enriched Tissue enhanced duodenum: 2.5;esophagus: 5.4;testis: 2.7 urinary bladder: 1.4 DMBT1 GP340, muclin ENSG00000187908 Deleted in malignant brain tumors 1 10 122560665-122643736 Disease related genes, Predicted secreted proteins Evidence at protein level HPA040778 Supported Endometrial cancer:1.43e-4 (favourable) Group enriched Tissue enhanced duodenum: 876.2;small intestine: 299.5 salivary gland: 145.2 DQX1 FLJ23757 ENSG00000144045 DEAQ box RNA-dependent ATPase 1 2 74518131-74526336 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039158 Supported Approved Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 14.8;small intestine: 13.8 colon: 5.6 EDN3 ET3 ENSG00000124205 Endothelin 3 20 59300427-59325992 Disease related genes, Predicted secreted proteins Evidence at protein level Glioma:2.38e-4 (favourable) Mixed Tissue enhanced duodenum: 39.3;small intestine: 40.2 thyroid gland: 36.2 ENTPD8 NTPDase-8, UNQ2492 ENSG00000188833 Ectonucleoside triphosphate diphosphohydrolase 8 9 137434364-137441816 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA021509 Supported Approved Nucleoplasm
Vesicles
Cytosol Stomach cancer:7.17e-4 (favourable) Mixed Tissue enhanced colon: 22.2;duodenum: 29.5;small intestine: 32.1 rectum: 12.7 ESCO2 EFO2, RBS ENSG00000171320 Establishment of sister chromatid cohesion N-acetyltransferase 2 8 27771949-27812640 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA027243, HPA053679 Supported Nucleus
Golgi apparatus Colorectal cancer:1.04e-4 (favourable) Mixed Tissue enhanced duodenum: 11.5 testis: 10.4 EXOC3L4 C14orf73 ENSG00000205436 Exocyst complex component 3-like 4 14 103100144-103110559 Predicted intracellular proteins Evidence at protein level HPA043661 Uncertain Colorectal cancer:1.43e-5 (unfavourable) Tissue enhanced Tissue enhanced duodenum: 19.7 small intestine: 11.0 FAM132A C1QDC2, C1QTNF12, CTRP12, MGC105127 ENSG00000184163 Family with sequence similarity 132, member A 1 1242446-1246722 Predicted secreted proteins Evidence at protein level HPA024107 Approved Approved Vesicles Mixed Tissue enhanced duodenum: 7.1;small intestine: 7.5 colon: 2.2 FAM3B 2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44 ENSG00000183844 Family with sequence similarity 3, member B 21 41304212-41357431 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015885, HPA029777 Approved Approved Vesicles Tissue enhanced Tissue enhanced duodenum: 166.7;small intestine: 170.3 stomach: 124.7 FAM83E FLJ20200 ENSG00000105523 Family with sequence similarity 83, member E 19 48600810-48614854 Predicted intracellular proteins Evidence at protein level HPA049305 Uncertain Mixed Tissue enhanced duodenum: 31.7;small intestine: 36.0;stomach: 41.5 colon: 23.0 FBP1 FBP ENSG00000165140 Fructose-1,6-bisphosphatase 1 9 94603133-94640249 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005857, HPA012513, CAB033869 Supported Uncertain Mitochondria Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable) Expressed in all Tissue enhanced duodenum: 338.7;liver: 442.9 small intestine: 286.0 FEV Pet-1 ENSG00000163497 FEV (ETS oncogene family) 2 218981087-218985657 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA067679 Supported Approved Nuclear speckles Pancreatic cancer:4.85e-4 (favourable) Group enriched Tissue enhanced adrenal gland: 2.1;duodenum: 3.0;stomach: 2.4 prostate: 1.9 FUT2 SE, Se2, SEC2, sej ENSG00000176920 Fucosyltransferase 2 (secretor status included) 19 48695971-48705950 Blood group antigen proteins, Enzymes, Predicted membrane proteins Evidence at transcript level HPA014402 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:5.83e-4 (favourable) Mixed Tissue enhanced duodenum: 52.9 stomach: 32.5 GAGE12B ENSG00000236737 G antigen 12B X 49529869-49529985 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced duodenum: 1.2 spleen,stomach: 0.4 GAL3ST1 CST ENSG00000128242 Galactose-3-O-sulfotransferase 1 22 30554635-30574587 Enzymes, Predicted secreted proteins Evidence at protein level HPA001220 Approved Approved Vesicles Renal cancer:1.79e-4 (unfavourable) Tissue enriched Tissue enhanced duodenum: 23.9;small intestine: 27.7 cerebral cortex: 18.2 GATA4 ENSG00000136574 GATA binding protein 4 8 11676959-11760002 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB013125, HPA073899 Uncertain Supported Nuclear bodies Tissue enhanced Tissue enhanced duodenum: 74.5;heart muscle: 61.7;ovary: 111.8 testis: 51.4 GATA5 bB379O24.1, GATAS ENSG00000130700 GATA binding protein 5 20 62463497-62475970 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA067583 Approved Nucleoplasm
Cytosol Tissue enhanced Tissue enhanced duodenum: 11.7;small intestine: 11.3;testis: 8.8 stomach: 7.6 GCNT4 C2GNT3 ENSG00000176928 Glucosaminyl (N-acetyl) transferase 4, core 2 5 75025346-75030899 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037431 Approved Supported Nucleoplasm
Golgi apparatus Renal cancer:1.93e-7 (favourable) Mixed Tissue enhanced duodenum: 22.0 parathyroid gland: 20.7 GDA ENSG00000119125 Guanine deaminase 9 72114595-72257193 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019352, HPA024099, HPA030387 Supported Approved Nucleus Renal cancer:2.66e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 102.6;duodenum: 97.8;small intestine: 106.3 kidney: 43.2 GHRH GHRF ENSG00000118702 Growth hormone releasing hormone 20 37251082-37261835 Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced duodenum: 3.5;heart muscle: 1.8 adrenal gland: 1.4 GLOD5 ENSG00000171433 Glyoxalase domain containing 5 X 48761750-48773648 Predicted intracellular proteins Evidence at protein level HPA010667 Uncertain Uncertain Mitochondria Mixed Tissue enhanced duodenum: 11.1;kidney: 10.9;small intestine: 10.9 epididymis: 6.7 GLTPD2 ENSG00000182327 Glycolipid transfer protein domain containing 2 17 4788959-4790390 Predicted secreted proteins Evidence at protein level HPA058295, HPA065267 Uncertain Approved Vesicles Tissue enriched Tissue enhanced duodenum: 11.3;kidney: 12.9;liver: 14.0 small intestine: 7.4 GLYCTK HBEBP2, HBEBP4 ENSG00000168237 Glycerate kinase 3 52287089-52293476 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA006913 Approved Approved Golgi apparatus
Cytosol
Rods & Rings Head and neck cancer:1.64e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 39.3;liver: 60.5 small intestine: 32.4 GNAT3 GDCA, gustducin ENSG00000214415 Guanine nucleotide binding protein, alpha transducing 3 7 80458671-80512020 Predicted intracellular proteins Evidence at protein level Group enriched Tissue enhanced duodenum: 2.0;small intestine: 1.4 testis: 0.5 GNG13 G(gamma)13, h2-35 ENSG00000127588 Guanine nucleotide binding protein (G protein), gamma 13 16 798041-800733 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA046272 Approved Mixed Tissue enhanced cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.5 colon,testis: 0.7 GOLT1A CGI-141, FLJ42654, GOT1, MGC62027, YMR292W ENSG00000174567 Golgi transport 1A 1 204198160-204214092 Predicted membrane proteins Evidence at protein level Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable) Tissue enriched Tissue enhanced duodenum: 41.5;liver: 78.8;small intestine: 43.2 parathyroid gland: 27.5 GPR35 ENSG00000178623 G protein-coupled receptor 35 2 240605431-240631259 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable) Tissue enhanced Tissue enhanced duodenum: 42.6;small intestine: 43.2 colon: 18.8 GSDMB GSDML, PRO2521 ENSG00000073605 Gasdermin B 17 39904595-39919854 Predicted intracellular proteins Evidence at protein level CAB013681, HPA023925, HPA052407 Supported Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable) Expressed in all Tissue enhanced duodenum: 68.8;small intestine: 86.7 rectum: 63.5 HIST1H2BH H2B/j, H2BFJ ENSG00000275713 Histone cluster 1, H2bh 6 26251651-26253710 Predicted intracellular proteins Evidence at protein level HPA042205, HPA043013, HPA048671 Supported Approved Nucleoplasm
Cytosol Head and neck cancer:7.52e-4 (unfavourable) Mixed Tissue enhanced duodenum: 3.1 small intestine: 1.2 HKDC1 FLJ22761, FLJ37767 ENSG00000156510 Hexokinase domain containing 1 10 69220303-69267559 Enzymes, Predicted intracellular proteins Evidence at protein level HPA011956, HPA064198, HPA064230 Approved Validated Mitochondria Mixed Tissue enhanced duodenum: 54.6;small intestine: 53.3 thyroid gland: 15.1 HNF1A HCF-1A, HNF1, LFB1, MODY3, TCF1 ENSG00000135100 HNF1 homeobox A 12 120978543-121002512 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010430, HPA035231 Supported Supported Nucleoplasm Mixed Tissue enhanced duodenum: 15.9;kidney: 10.1;small intestine: 16.0 liver: 5.8 HRASLS2 FLJ20556 ENSG00000133328 HRAS-like suppressor 2 11 63552770-63563383 Predicted membrane proteins Evidence at protein level HPA058997 Approved Approved Mitochondria Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable) Mixed Tissue enhanced duodenum: 69.6;small intestine: 47.5 rectum: 14.7 HSD17B2 HSD17, SDR9C2 ENSG00000086696 Hydroxysteroid (17-beta) dehydrogenase 2 16 82035004-82098534 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021826, HPA050235 Supported Approved Endoplasmic reticulum Urothelial cancer:3.83e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 443.2;placenta: 548.0 small intestine: 204.1 HTR3E ENSG00000186038 5-hydroxytryptamine (serotonin) receptor 3E, ionotropic 3 184097064-184106995 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049764 Supported Not detected Tissue enhanced duodenum: 1.0 small intestine: 0.8 HTR4 5-HT4 ENSG00000164270 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled 5 148451032-148677235 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040591 Approved Not detected Tissue enhanced duodenum: 5.0;small intestine: 10.2 heart muscle: 3.5 ITPKA IP3-3KA, IP3KA ENSG00000137825 Inositol-trisphosphate 3-kinase A 15 41493393-41503551 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040454 Approved Approved Approved Vesicles Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 25.8;duodenum: 18.2;small intestine: 20.2 stomach: 9.1 KCNK10 K2p10.1, PPP1R97, TREK-2, TREK2 ENSG00000100433 Potassium channel, two pore domain subfamily K, member 10 14 88180103-88326907 Predicted membrane proteins Evidence at protein level HPA030462 Approved Mixed Tissue enhanced cerebral cortex: 5.6;duodenum: 5.3 small intestine: 2.8 KCNK16 K2p16.1, TALK-1, TALK1 ENSG00000095981 Potassium channel, two pore domain subfamily K, member 16 6 39314698-39322968 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Tissue enriched Tissue enhanced duodenum: 3.9;pancreas: 5.4;stomach: 12.6 thyroid gland: 1.7 KRT20 CK20, K20, MGC35423 ENSG00000171431 Keratin 20, type I 17 40875941-40885227 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000032, HPA024309, HPA024684, HPA027236 Supported Approved Cytosol Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable) Group enriched Tissue enhanced colon: 361.8;duodenum: 259.3;rectum: 299.7;small intestine: 509.8 stomach: 83.3 LBX2 ENSG00000179528 Ladybird homeobox 2 2 74497517-74503316 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA044257 Uncertain Approved Nucleus
Midbody Mixed Tissue enhanced duodenum: 5.5;small intestine: 5.4 liver: 3.5 LCN15 PRO6093, UNQ2541 ENSG00000177984 Lipocalin 15 9 136759634-136766255 Predicted secreted proteins Evidence at protein level HPA060584 Approved Tissue enriched Tissue enhanced duodenum: 12.4;seminal vesicle: 4.8;small intestine: 4.1 colon: 2.8 LGALS4 GAL4 ENSG00000171747 Lectin, galactoside-binding, soluble, 4 19 38801671-38813364 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025653, HPA031184, HPA031185, HPA031186 Supported Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable) Group enriched Tissue enhanced colon: 749.2;duodenum: 541.6;rectum: 652.0;small intestine: 503.3 gallbladder: 139.4 LHB CGB4, hLHB, LSH-B ENSG00000104826 Luteinizing hormone beta polypeptide 19 49015980-49017090 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB022241, CAB022707, HPA038925, HPA038934 Supported Approved Cytosol Pancreatic cancer:6.78e-4 (unfavourable) Mixed Tissue enhanced duodenum: 3.3;pancreas: 4.8;testis: 3.1 skin: 0.8 LMX1A LMX1, LMX1.1 ENSG00000162761 LIM homeobox transcription factor 1, alpha 1 165201867-165356715 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028051, HPA030088 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles Not detected Tissue enhanced duodenum: 1.1;testis: 2.4 adipose tissue,rectum,small intestine: 0.6 LRRC66 ENSG00000188993 Leucine rich repeat containing 66 4 51993702-52017620 Predicted membrane proteins Evidence at transcript level HPA014549, HPA027839 Uncertain Mixed Tissue enhanced duodenum: 23.2;small intestine: 21.0 rectum: 6.5 LRRC75A C17orf76, FAM211A, FLJ35696 ENSG00000181350 Leucine rich repeat containing 75A 17 16441577-16492153 Predicted intracellular proteins Evidence at protein level HPA028528 Uncertain Pancreatic cancer:7.46e-5 (favourable) Mixed Tissue enhanced duodenum: 11.3;small intestine: 11.2 spleen: 5.6 MGAM MGA ENSG00000257335 Maltase-glucoamylase 7 141907813-142106747 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002270 Supported Renal cancer:6.16e-5 (favourable) Tissue enriched Tissue enhanced duodenum: 61.0;small intestine: 99.1 epididymis: 30.6 MINOS1-NBL1 ENSG00000270136 MINOS1-NBL1 readthrough 1 19596979-19658056 Predicted secreted proteins Evidence at transcript level HPA007394 Uncertain Not detected Tissue enhanced duodenum: 16.6;small intestine: 17.5 adipose tissue: 13.7 MLXIPL bHLHd14, CHREBP, MIO, MONDOB, WBSCR14, WS-bHLH ENSG00000009950 MLX interacting protein-like 7 73593194-73624543 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA064640 Supported Nucleus Tissue enriched Tissue enhanced adipose tissue: 60.8;duodenum: 60.3 liver: 47.2 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MNX1 HB9, HLXB9, HOXHB9, SCRA1 ENSG00000130675 Motor neuron and pancreas homeobox 1 7 156994051-157010651 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA071717 Approved Nucleus
Nucleoli
Cytosol Mixed Tissue enhanced duodenum: 7.5;small intestine: 6.8 colon: 3.8 MS4A18 ENSG00000214782 Membrane-spanning 4-domains, subfamily A, member 18 11 60729304-60744212 Predicted membrane proteins Evidence at transcript level HPA045121 Approved Not detected Tissue enhanced breast: 10.3;duodenum: 24.5 small intestine: 4.1 MS4A8 CD20L5, MS4A4, MS4A8B ENSG00000166959 Membrane-spanning 4-domains, subfamily A, member 8 11 60699574-60715811 Predicted membrane proteins Evidence at protein level HPA007318, HPA007319 Supported Tissue enhanced Tissue enhanced duodenum: 191.8;fallopian tube: 223.5;small intestine: 215.2 stomach: 49.6 MT1B MT1, MT1Q ENSG00000169688 Metallothionein 1B 16 56651899-56653204 Predicted intracellular proteins Evidence at protein level Tissue enriched Tissue enhanced duodenum: 1.3;liver: 3.2 appendix: 0.5 MUC3A MUC3 ENSG00000169894 Mucin 3A, cell surface associated 7 100949555-100968346 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA010871 Uncertain Tissue enhanced Tissue enhanced duodenum: 42.7;gallbladder: 21.9;small intestine: 37.9 rectum: 14.7 MYO1A DFNA48, MYHL ENSG00000166866 Myosin IA 12 57028517-57051198 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA053490 Supported Group enriched Tissue enhanced duodenum: 342.4;small intestine: 345.5 rectum: 73.2 MYO7B ENSG00000169994 Myosin VIIB 2 127535802-127637729 Predicted intracellular proteins Evidence at protein level HPA039131 Approved Renal cancer:1.25e-4 (favourable) Group enriched Tissue enhanced duodenum: 117.1;small intestine: 94.0 colon: 35.9 NAGS AGAS, ARGA, NAT7 ENSG00000161653 N-acetylglutamate synthase 17 44004546-44009063 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027300 Supported Mitochondria Expressed in all Tissue enhanced duodenum: 15.2;small intestine: 13.9 parathyroid gland: 5.4 NAPRT NAPRT1, PP3856 ENSG00000147813 Nicotinate phosphoribosyltransferase 8 143574785-143578649 Enzymes, Predicted intracellular proteins Evidence at protein level HPA023739, HPA024017, CAB068206, CAB068207 Approved Approved Nucleus
Golgi apparatus
Cytosol Renal cancer:6.28e-4 (favourable) Expressed in all Tissue enhanced duodenum: 22.0;small intestine: 21.1 bone marrow: 9.7 NDUFC2-KCTD14 ENSG00000259112 NDUFC2-KCTD14 readthrough 11 78016971-78079865 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038873, HPA056195 Approved Supported Mitochondria Not detected Tissue enhanced duodenum: 5.1 stomach: 2.6 NEUROD1 BETA2, BHF-1, bHLHa3, MODY6, NEUROD ENSG00000162992 Neuronal differentiation 1 2 181673088-181680876 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003278, CAB022450 Approved Glioma:6.83e-5 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 6.0;duodenum: 6.2;small intestine: 4.5;stomach: 4.9 pancreas: 1.8 NEUROG3 Atoh5, bHLHa7, Math4B, ngn3 ENSG00000122859 Neurogenin 3 10 69571698-69573238 Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA039785 Uncertain Tissue enhanced Tissue enhanced duodenum: 2.9;small intestine: 1.3 colon,rectum: 0.4 NKX6-3 FLJ25169 ENSG00000165066 NK6 homeobox 3 8 41645178-41650669 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA042790 Uncertain Group enriched Tissue enhanced duodenum: 17.7;stomach: 51.1 parathyroid gland: 7.8 NPC1L1 ENSG00000015520 NPC1-like 1 7 44512535-44541315 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB070127, CAB070128 Supported Group enriched Tissue enhanced duodenum: 58.7;small intestine: 59.3 liver: 14.2 NR0B2 SHP ENSG00000131910 Nuclear receptor subfamily 0, group B, member 2 1 26911489-26913966 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Group enriched Tissue enhanced duodenum: 80.8;liver: 48.6 small intestine: 29.6 OLFM4 GC1, GW112, OlfD ENSG00000102837 Olfactomedin 4 13 53028759-53052057 Predicted secreted proteins Evidence at protein level Breast cancer:8.77e-4 (favourable) Group enriched Tissue enhanced duodenum: 1226.8;rectum: 621.3;small intestine: 1466.5 colon: 454.6 OMP ENSG00000254550 Olfactory marker protein 11 77102840-77103331 Predicted intracellular proteins Evidence at transcript level Mixed Tissue enhanced duodenum: 2.7;small intestine: 2.8 rectum: 2.0 ONECUT2 OC-2 ENSG00000119547 One cut homeobox 2 18 57435685-57491297 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA057058 Approved Supported Nucleoplasm
Actin filaments Group enriched Tissue enhanced duodenum: 10.6;gallbladder: 16.4 liver: 4.5 PAX4 MODY9 ENSG00000106331 Paired box 4 7 127610292-127615928 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level Not detected Tissue enhanced duodenum: 1.2;rectum: 1.3 small intestine,testis: 0.6 PDZD3 FLJ22756, IKEPP, PDZK2 ENSG00000172367 PDZ domain containing 3 11 119185457-119190223 Predicted intracellular proteins Evidence at protein level Tissue enhanced Tissue enhanced duodenum: 17.8;kidney: 10.8;small intestine: 21.6 rectum: 6.8 PIGR ENSG00000162896 Polymeric immunoglobulin receptor 1 206928518-206946466 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006154, CAB009454, HPA012012 Supported Uncertain Nucleus
Nucleoli
Cytosol Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable) Tissue enhanced Tissue enhanced colon: 1721.7;duodenum: 2732.8 rectum: 1357.3 PLS1 I-plastin, Plastin-1 ENSG00000120756 Plastin 1 3 142596387-142713664 Predicted intracellular proteins Evidence at protein level HPA055744 Supported Renal cancer:8.76e-6 (favourable), Pancreatic cancer:4.84e-4 (unfavourable) Mixed Tissue enhanced duodenum: 197.8;small intestine: 355.4 rectum: 154.7 PRR15L ATAD4, MGC11242 ENSG00000167183 Proline rich 15-like 17 47951967-47957878 Predicted intracellular proteins Evidence at protein level HPA022918 Approved Approved Cytosol Renal cancer:6.29e-13 (favourable), Stomach cancer:1.69e-5 (favourable) Mixed Tissue enhanced duodenum: 185.5 small intestine: 144.4 PTPRH SAP-1 ENSG00000080031 Protein tyrosine phosphatase, receptor type, H 19 55181248-55209506 Enzymes, Predicted membrane proteins Evidence at protein level HPA042300 Approved Mitochondria Mixed Tissue enhanced duodenum: 70.8;small intestine: 78.5 gallbladder: 38.8 REG1B PSPS2, REGH, REGI-BETA, REGL ENSG00000172023 Regenerating islet-derived 1 beta 2 79085030-79088019 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045549, HPA045579 Supported Tissue enhanced Tissue enhanced duodenum: 755.9;small intestine: 443.6 pancreas: 181.5 RNF186 FLJ20225 ENSG00000178828 Ring finger protein 186 1 19814029-19815278 Predicted membrane proteins Evidence at protein level HPA034547, HPA035558 Supported Tissue enhanced Tissue enhanced duodenum: 136.0;epididymis: 82.8;small intestine: 47.7 kidney: 26.4 RP11-697E2.12 ENSG00000275674 15 90266317-90314499 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced duodenum: 1.2 cerebral cortex,small intestine: 0.8 RP13-1032I1.10 ENSG00000262660 17 81703371-81720539 Predicted intracellular proteins Evidence at protein level HPA022853, HPA023043, HPA023048 Approved Validated Mitochondria Not detected Tissue enhanced cerebral cortex: 1.1;duodenum: 2.1 small intestine: 0.8 RP13-672B3.2 ENSG00000256632 12 132688049-132714912 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced duodenum: 2.7 kidney,small intestine,testis: 0.6 RXFP4 GPCR142, GPR100, RLN3R2, RXFPR4 ENSG00000173080 Relaxin/insulin-like family peptide receptor 4 1 155941710-155942949 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enhanced colon: 2.2;duodenum: 1.4;rectum: 2.6 small intestine: 1.1 SCTR ENSG00000080293 Secretin receptor 2 119439843-119525301 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA007269 Uncertain Tissue enhanced Tissue enhanced duodenum: 27.4;lung: 13.0;pancreas: 14.3 stomach: 4.2 SDCBP2 SITAC18, ST-2 ENSG00000125775 Syndecan binding protein (syntenin) 2 20 1309909-1329239 Predicted intracellular proteins Evidence at protein level HPA054554 Approved Vesicles
Cytosol Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable) Expressed in all Tissue enhanced duodenum: 138.8;small intestine: 146.8 stomach: 96.4 SEC16B LZTR2, PGPR-p117, RGPR, Sec16S ENSG00000120341 SEC16 homolog B, endoplasmic reticulum export factor 1 177923956-177984303 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031202, HPA054292 Uncertain Approved Endoplasmic reticulum
Plasma membrane
Actin filaments Not detected Tissue enhanced duodenum: 28.9;small intestine: 31.5 liver: 18.8 SFRP5 SARP3 ENSG00000120057 Secreted frizzled-related protein 5 10 97766751-97771952 Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced duodenum: 31.7;pancreas: 31.2;small intestine: 30.0 adrenal gland: 13.0 SH2D6 FLJ35993 ENSG00000152292 SH2 domain containing 6 2 85418721-85437029 Predicted intracellular proteins Evidence at transcript level HPA053873 Uncertain Mixed Tissue enhanced duodenum: 4.1;testis: 4.7;thyroid gland: 3.9 small intestine: 2.7 SLC13A2 NaDC-1 ENSG00000007216 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 17 28473293-28497781 Predicted membrane proteins, Transporters Evidence at protein level HPA014963 Supported Renal cancer:9.00e-4 (favourable) Mixed Tissue enhanced duodenum: 70.6;small intestine: 55.4 kidney: 19.6 SLC22A18 BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5 ENSG00000110628 Solute carrier family 22, member 18 11 2899721-2925246 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA067812, HPA071461 Approved Expressed in all Tissue enhanced duodenum: 44.5;small intestine: 32.4 colon: 10.5 SLC22A18AS BWR1B, BWSCR1B, ORCTL2S, p27-BWR1B, SLC22A1LS ENSG00000254827 Solute carrier family 22 (organic cation transporter), member 18 antisense 11 2887780-2903740 Predicted intracellular proteins Evidence at protein level HPA068288 Supported Supported Nucleoplasm Mixed Tissue enhanced colon: 14.7;duodenum: 13.9 rectum,small intestine: 11.2 SLC25A34 DKFZp781A10161 ENSG00000162461 Solute carrier family 25, member 34 1 15736405-15741396 Predicted membrane proteins, Transporters Evidence at protein level HPA069806 Supported Mitochondria Mixed Tissue enhanced duodenum: 14.9;small intestine: 15.5 skeletal muscle: 8.2 SLC26A3 CLD, DRA ENSG00000091138 Solute carrier family 26 (anion exchanger), member 3 7 107765467-107803225 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA036055 Approved Tissue enriched Tissue enhanced colon: 1092.5;duodenum: 594.0;rectum: 974.8 seminal vesicle: 183.9 SLC28A2 CNT2, HCNT2, HsT17153, SPNT1 ENSG00000137860 Solute carrier family 28 (concentrative nucleoside transporter), member 2 15 45252230-45277845 Predicted membrane proteins, Transporters Evidence at protein level HPA046068, HPA055623 Supported Tissue enhanced Tissue enhanced duodenum: 66.8;rectum: 37.9;small intestine: 100.1 stomach: 21.4 SLC2A5 GLUT5 ENSG00000142583 Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 1 9035107-9088478 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005449 Supported Renal cancer:5.44e-5 (unfavourable) Group enriched Tissue enhanced duodenum: 112.1;small intestine: 94.6;testis: 139.5 bone marrow: 64.6 SLC30A10 DKFZp547M236, ZnT-10, ZNT8, ZRC1 ENSG00000196660 Solute carrier family 30, member 10 1 219685427-219958647 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017989 Uncertain Tissue enriched Tissue enhanced duodenum: 2.2;liver: 2.3 testis: 1.1 SLC37A4 G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d ENSG00000137700 Solute carrier family 37 (glucose-6-phosphate transporter), member 4 11 119024114-119030906 Predicted membrane proteins Evidence at protein level HPA038939, HPA038940 Approved Approved Mitochondria Expressed in all Tissue enhanced duodenum: 31.4;kidney: 36.1 epididymis: 20.7 SLC44A4 C6orf29, CTL4, FLJ14491, NG22, TPPT ENSG00000204385 Solute carrier family 44, member 4 6 31863192-31879046 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046977, HPA054176 Approved Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 36.0 prostate: 30.1 SLC4A7 NBC3, SBC2, SLC4A6 ENSG00000033867 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 3 27372721-27484420 Predicted membrane proteins, Transporters Evidence at protein level CAB022494, HPA035857 Supported Supported Plasma membrane
Focal adhesion sites Renal cancer:7.91e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 59.2 breast: 23.6 SLC51A OSTalpha ENSG00000163959 Solute carrier family 51, alpha subunit 3 196211487-196243178 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA039123 Approved Liver cancer:7.54e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 30.1;liver: 35.2;small intestine: 72.7 colon: 10.2 SLC51B OSTbeta ENSG00000186198 Solute carrier family 51, beta subunit 15 65045370-65053396 Predicted membrane proteins, Transporters Evidence at protein level HPA008398, HPA008533 Supported Approved Vesicles
Mitochondria Renal cancer:8.46e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 87.8;small intestine: 120.6 cervix, uterine: 63.7 SLC6A20 XT3, Xtrp3 ENSG00000163817 Solute carrier family 6 (proline IMINO transporter), member 20 3 45755450-45796535 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029873 Approved Renal cancer:1.55e-5 (favourable) Mixed Tissue enhanced duodenum: 25.1;small intestine: 19.7 gallbladder: 10.9 SMPD3 NSMASE2 ENSG00000103056 Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 16 68358325-68448688 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033885, HPA065535, HPA069383 Approved Supported Endoplasmic reticulum Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable) Mixed Tissue enhanced duodenum: 62.7;small intestine: 64.1 stomach: 22.9 SOAT2 ACAT2 ENSG00000167780 Sterol O-acyltransferase 2 12 53103518-53124538 Enzymes, Predicted membrane proteins Evidence at protein level HPA062409 Uncertain Group enriched Tissue enhanced duodenum: 12.4;small intestine: 22.4 spleen: 3.5 SOWAHA ANKRD43 ENSG00000198944 Sosondowah ankyrin repeat domain family member A 5 132813587-132816797 Predicted secreted proteins Evidence at protein level HPA064621 Approved Renal cancer:9.38e-5 (favourable), Pancreatic cancer:4.03e-4 (favourable) Mixed Tissue enhanced duodenum: 40.8;small intestine: 47.6 cerebral cortex: 22.2 SST SMST ENSG00000157005 Somatostatin 3 187668906-187670399 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000075, HPA019472 Supported Supported Endometrial cancer:1.93e-5 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 212.6;duodenum: 387.3;stomach: 304.0 small intestine: 145.4 SSTR1 ENSG00000139874 Somatostatin receptor 1 14 38207999-38213067 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031506 Approved Renal cancer:4.28e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 13.6;duodenum: 14.6;stomach: 21.4 small intestine: 9.3 SSUH2 C3orf32, fls485, ssu-2 ENSG00000125046 Ssu-2 homolog (C. elegans) 3 8619400-8745040 Predicted intracellular proteins Evidence at protein level HPA049777 Uncertain Mixed Tissue enhanced duodenum: 4.3;small intestine: 4.0;testis: 4.0 spleen: 1.6 SULT1A2 HAST4, STP2 ENSG00000197165 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 16 28591943-28597109 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049500, HPA051051 Supported Tissue enhanced Tissue enhanced duodenum: 50.6;small intestine: 50.2 liver: 20.9 SULT1A4 ENSG00000213648 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 4 16 29459889-29464976 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049500, HPA051051 Supported Not detected Tissue enhanced duodenum: 178.1;small intestine: 133.7 colon: 39.3 TGFBR3L ENSG00000260001 Transforming growth factor, beta receptor III-like 19 7916145-7919097 Predicted membrane proteins Evidence at transcript level HPA074356 Approved Vesicles Mixed Tissue enhanced duodenum: 1.8;small intestine: 1.8 kidney: 1.2 TJP3 ZO-3 ENSG00000105289 Tight junction protein 3 19 3708109-3750813 Predicted intracellular proteins Evidence at protein level CAB013244, HPA046863, HPA053337 Supported Validated Nucleoplasm
Cell Junctions Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable) Mixed Tissue enhanced duodenum: 42.7;small intestine: 42.1 colon: 31.1 TMC4 ENSG00000167608 Transmembrane channel-like 4 19 54160108-54173250 Predicted membrane proteins Evidence at protein level HPA048635 Approved Renal cancer:1.54e-8 (favourable) Expressed in all Tissue enhanced duodenum: 31.3 small intestine: 22.6 TMEM139 FLJ90586 ENSG00000178826 Transmembrane protein 139 7 143279957-143288048 Predicted membrane proteins, Transporters Evidence at protein level HPA036982, HPA036983 Approved Approved Plasma membrane
Focal adhesion sites Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable) Mixed Tissue enhanced duodenum: 34.9;kidney: 34.4 small intestine: 21.2 TMEM150B TMEM224 ENSG00000180061 Transmembrane protein 150B 19 55312801-55334048 Predicted membrane proteins Evidence at transcript level Renal cancer:6.14e-6 (unfavourable) Tissue enhanced Tissue enhanced duodenum: 71.8;small intestine: 67.8 lung: 18.9 TMEM229A ENSG00000234224 Transmembrane protein 229A 7 124030916-124033023 Predicted membrane proteins Evidence at protein level HPA056391 Uncertain Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 7.1;duodenum: 8.9;testis: 10.4 small intestine: 4.4 TMEM45B BC016153, FLJ40787 ENSG00000151715 Transmembrane protein 45B 11 129815819-129860003 Predicted membrane proteins Evidence at protein level HPA015878 Approved Uncertain Nucleoplasm
Cytosol Expressed in all Tissue enhanced duodenum: 140.0;small intestine: 141.9 rectum: 104.8 TMEM82 ENSG00000162460 Transmembrane protein 82 1 15742422-15747982 Predicted membrane proteins Evidence at protein level HPA060282 Uncertain Renal cancer:3.80e-7 (favourable) Tissue enhanced Tissue enhanced duodenum: 23.7;liver: 9.0;small intestine: 19.8 kidney: 7.6 TMEM92 FLJ33318 ENSG00000167105 Transmembrane protein 92 17 50271406-50281485 Predicted membrane proteins Evidence at protein level HPA063009, HPA069820 Approved Supported Nucleoplasm Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable) Mixed Tissue enhanced duodenum: 41.4;small intestine: 51.6 gallbladder: 21.9 TNFRSF11A CD265, FEO, LOH18CR1, PDB2, RANK ENSG00000141655 Tumor necrosis factor receptor superfamily, member 11a, NFKB activator 18 62325287-62391292 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010391, HPA027728, HPA047976 Uncertain Supported Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 31.2 small intestine: 20.9 TPSG1 PRSS31, TMT ENSG00000116176 Tryptase gamma 1 16 1221651-1225257 Enzymes, Predicted membrane proteins Evidence at transcript level HPA060458 Approved Renal cancer:1.76e-8 (unfavourable) Tissue enhanced Tissue enhanced colon: 15.2;duodenum: 14.7;small intestine: 10.7 rectum: 9.8 TREH MGC129621, TRE, TREA ENSG00000118094 Trehalase (brush-border membrane glycoprotein) 11 118657316-118679690 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA039913, HPA042045 Supported Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable) Mixed Tissue enhanced duodenum: 62.3;small intestine: 74.1 kidney: 14.7 TRIM15 RNF93, ZNF178, ZNFB7 ENSG00000204610 Tripartite motif containing 15 6 30163206-30172696 Predicted intracellular proteins Evidence at protein level HPA047527 Uncertain Tissue enhanced Tissue enhanced colon: 2.7;duodenum: 3.7 appendix,small intestine: 1.1 TSPAN8 CO-029, TM4SF3 ENSG00000127324 Tetraspanin 8 12 71125085-71441898 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB026009, HPA044337 Supported Approved Nucleoplasm Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable) Tissue enhanced Tissue enhanced colon: 926.1;duodenum: 931.2;rectum: 922.7;small intestine: 928.3 stomach: 574.1 TUBAL3 FLJ21665 ENSG00000178462 Tubulin, alpha-like 3 10 5393098-5404830 Predicted intracellular proteins Evidence at protein level HPA045900, HPA063394 Uncertain Tissue enhanced Tissue enhanced duodenum: 25.1;small intestine: 31.7 colon: 12.0 UCN3 SPC, UCNIII ENSG00000178473 Urocortin 3 10 5365009-5374692 Predicted secreted proteins Evidence at protein level HPA038281 Uncertain Group enriched Tissue enhanced duodenum: 9.5;small intestine: 7.6 stomach: 3.7 UGT1A10 UGT1J ENSG00000242515 UDP glucuronosyltransferase 1 family, polypeptide A10 2 233636454-233773305 Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:4.55e-4 (unfavourable) Tissue enhanced Tissue enhanced colon: 50.4;duodenum: 83.1;small intestine: 60.3 rectum: 40.2 UGT2A3 FLJ21934 ENSG00000135220 UDP glucuronosyltransferase 2 family, polypeptide A3 4 68928463-68951791 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Supported Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 84.3;gallbladder: 46.5;kidney: 46.4;small intestine: 87.8 rectum: 24.3 UGT2B17 ENSG00000197888 UDP glucuronosyltransferase 2 family, polypeptide B17 4 68537184-68568527 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Supported Group enriched Tissue enhanced colon: 378.9;duodenum: 381.0;small intestine: 532.1 rectum: 153.4 UNC5CL MGC34763, ZUD ENSG00000124602 Unc-5 family C-terminal like 6 41026911-41039217 Predicted intracellular proteins Evidence at protein level HPA015725 Supported Approved Centrosome Mixed Tissue enhanced duodenum: 38.3;small intestine: 33.1;stomach: 24.0 kidney: 14.9 UNC5D KIAA1777, Unc5h4 ENSG00000156687 Unc-5 netrin receptor D 8 35235457-35796550 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042940 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.2;duodenum: 6.2;prostate: 9.0 cervix, uterine: 3.4 UNC93A dJ366N23.1, dJ366N23.2 ENSG00000112494 Unc-93 homolog A (C. elegans) 6 167271169-167316019 Predicted membrane proteins Evidence at protein level HPA035729 Uncertain Tissue enhanced Tissue enhanced duodenum: 9.9;skin: 17.9 liver: 7.1 USH1C AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C ENSG00000006611 Usher syndrome 1C 11 17493895-17544416 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB013690, HPA027398, HPA027492, HPA028033 Supported Validated Cytosol Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable) Group enriched Tissue enhanced duodenum: 101.9;small intestine: 109.0 kidney: 55.1 XDH XO, XOR ENSG00000158125 Xanthine dehydrogenase 2 31334321-31414715 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062641, HPA069323 Supported Supported Nucleus Urothelial cancer:8.73e-6 (favourable) Mixed Tissue enhanced breast: 48.6;duodenum: 46.9;liver: 35.9;small intestine: 55.8 colon: 11.4